Statins and proteinuria
- Donald G. Vidt MD
- … show all 1 hide
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The proteinuria associated with 3-hydrodoxy-3-methylglutaryl coenzyme A reductase inhibitors is composed of primarily low-molecular weight proteins that disappear rapidly following discontinuation of the statin agent. More importantly, no evidence exists of nephrotoxicity or reduced renal function observed with the approved clinical dosages of any available statins. Recent clinical studies have suggested actual improvement in renal function demonstrated by decreases in creatinine concentrations and improvement in estimated glomerular filtration rates with both short-term and long-term administration of these agents. The progressive fibrosis and renal scarring of chronic kidney disease appears to be the end result of increased protein traffic in the proximal renal tubule. Early animal and recent clinical studies have suggested that treatment with statin agents in established chronic kidney disease can, in fact, provide renoprotection over and above that observed with aggressive blood pressure control and the use of angiotensin II antagonists.
- Oliver J, MacDowell M, Lee YC: Cellular mechanisms of protein metabolism in the nephron. I. The structural aspects of proteinuria; tubular absorption, droplet formation, and the disposal of proteins. J Exp Med 1954, 99:589–604. CrossRef
- Straus W: Cytochemical investigation of phagosomes and related structures in cryostat sections of the kidney and liver of rats after intravenous administration of horseradish peroxidase. Exp Cell Res 1962, 27:80–94. CrossRef
- Novikoff AB: The rat kidney; cytochemical and electron microscopic studies. In Ciba Foundation Symposium, Edited by Quinn EL, Kass EK. Boston: Little, Brown; 1960; 113–144.
- Christensen EI, Nielsen S: Structural and functional features of protein handling in the kidney proximal tubule. Semin Nephrol 1991, 11:414–439.
- Maack T: Renal filtration, transport and metabolism of protein. In The Kidney, edn 3. Edited by Seldin DW, Giebish G. Philadelphia: Lippincott, Williams & Wilkins; 2000: 2235–2267.
- Clague MJ: Molecular aspects of the endocytic pathway. Biochem J 1998, 336(Pt 2):271–282.
- Wall DA, Maack T: Endocytic uptake, transport, and catabolism of proteins by epithelial cells. Am J Physiol 1985, 248:C12-C20.
- Christensen EI, Birn H: Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol 2001, 280:F562-F573.
- Christensen EI, Birn H, Verroust P, Moestrup SK: Membrane receptors for endocytosis in the renal proximal tubule. Int Rev Cytol 1998, 180:237–284.
- Agarwal R: Statin induced proteinuria: renal injury or renoprotection? J Am Soc Nephrol 2004, 15:2502–2503. CrossRef
- Brunskill NJ, Cockcroft N, Nahorski S, Walls J: Albumin endocytosis is regulated by heterotrimeric GTP-binding protein G alpha i-3 in opossum kidney cells. Am J Physiol 1996, 271:F356-F364.
- Leheste JR, Rolinski B, Vorum H, et al.: Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol 1999, 155:1361–1370.
- Vidt DG, Cressman MD, Harris S, et al.: Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004, 102:52–60. CrossRef
- Schwegler JS, Heppelmann B, Mildenberger S, Silbernagl S: Receptor-mediated endocytosis of albumin in cultured opossum kidney cells: a model for proximal tubular protein reabsorption. Pflugers Arch 1991, 418:383–392. CrossRef
- Sidaway JE, Davidson RG, McTaggart F, et al.: Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 2004, 15:2258–2265. CrossRef
- Verhulst A, D’Haese PC, De Broe ME: Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 2004, 15:2249–2257. CrossRef
- Singhvi SM, Pan HY, Morrison RA, Willard DA: Disposition of pravastatin sodium, a tissue-selective HMG-GoA reductase inhibitor, in healthy subjects, Br J Clin Pharmacol 1990, 29:239–243.
- Martin PD, Warwick MJ, Dane AL, et al.: Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 2003, 25:2553–2563. CrossRef
- Endocrinologic and Metabolic Drugs Advisory Committee, July 9 2003, Food and Drug Administration Center for Drug Evaluation and Research. Department of Health and Human Services. 2003, Available at http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3968T1.doc. Accessed July 5, 2004.
- Pharmacology/Toxicology. DNA 21-366 Crestor July 9, 2003. Advisory Committee Briefing Document. Department of Health and Human Services. 2004. Available at http://www.fda.gov.ohrms/dockets/ac/03/briefing/3968B1 02 F-FDA-Pharm Tox%20Review.pdf. Accessed on July 5, 2004.
- Tonelli M, Moye L, Sacks FM, et al.: Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003, 138:98–104.
- Heart Protection Study Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7–22. CrossRef
- Collins R, Armitage J, Parish S, et al., for the Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005–2016. CrossRef
- Athyros VG, Mikhailidis DP, Papageorgiou AA, et al.: The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation GREACE. study. J Clin Pathol 2004, 57:728–734. CrossRef
- Remuzzi G, Ruggenenti P, Perico N: Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002, 136:604–615.
- Zoja C, Donadelli R, Colleoni S, et al.: Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation, Kidney Int 1998, 53:1608–1615. CrossRef
- Orisio S, Benigni A, Bruzzi I, et al.: Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993, 43:354–358.
- Eddy AA, Giachelli CM: Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 1995, 47:1546–1557. CrossRef
- Remuzzi G: Nephropathic nature of proteinuria. Curr Opin Nephrol Hypertens 1999, 8:665–663. CrossRef
- Comper WD, Osicka TM: Albumin-like material in urine. Kidney Int Suppl 2004, S65–S66.
- Eppel GA, Osicka TM, Pratt LM, et al.: The return of glomerular filtered albumin to the rat renal vein—the albumin retrieval pathway. Renal Fail 2001, 23:347–363. CrossRef
- Wharram BL, Goyal M, Gillespie PJ, et al.: Altered podocyte structure in GLEPP1 Ptpro.-deficient mice associated with hypertension and low glomerular filtration rate. J Clin Invest 2000, 106:1281–1290. CrossRef
- Hara M, Yanagihara T, Takada T, et al.: Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis. Am J Nephrol 1998, 18:35–41. CrossRef
- Nakamura T, Ushiyama C, Suzuki S, et al.: Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000, 15:1379–1383. CrossRef
- Kriz W, LeHir M: Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int 2005, 67:404–419. CrossRef
- Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005, 67:799–812. CrossRef
- Brouhard BH, Takamori H, Satoh S, et al.: The combination of lovastatin and enalapril in a model of progressive renal disease. Pediatr Nephrol 1994, 8:436–440. CrossRef
- Inman SR, Stowe NT, Cressman MD, et al.: Lovastatin preserves renal function in experimental diabetes. Am J Med Sci 1999, 317:215–221. CrossRef
- Liang K, Vaziri ND: HMG-CoA reductase inhibition with rosuvastatin improves hyperlipidemia and proteinuria and reverses LDL receptor and HDL receptor deficiencies in the nephrotic syndrome [abstract]. J Am Soc Nephrol 2003, 14:168A.
- Usui H, Shikata K, Matsuda M, et al.: HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 2003, 18:265–272. CrossRef
- Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001, 59:260–269. CrossRef
- Bianchi S, Bigazzi R, Ciazza A, Campese VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003, 41:565–570. CrossRef
- Lee TM, Su SF, Tsai CH: Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 2002, 40:67–73. CrossRef
- Tonolo G, Melis MG, Formato M, et al.: Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000, 30:980–987. CrossRef
- Perkins BA, Ficociello LH, Silva KH, et al.: Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003, 348:2285–2293. CrossRef
- Adam A, Raij L: Nitric oxide—angiotensin II axis in renal and cardiovascular injury. J Nephrol 2000, 13:211–220.
- Kurose I, Wolf R, Grisham MB, Granger DN: Modulation of ischemia/reperfusion-induced microvascular dysfunction by nitric oxide. Circ Res 1994, 74:376–382.
- Tesfamariam B, Frohlich BH, Gregg RE: Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity. J Cardiovasc Pharmacol 1999, 34:95–101. CrossRef
- Sposito AC, Mansur AP, Coelho OR, et al.: Additional reduction in blood pressure after cholesterol-lowering treatment by statins lovastatin or pravastatin. in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors enalapril or lisinopril. Am J Cardiol 1999, 83:1497–1499. CrossRef
- Ikeda T, Sakurai J, Nakayama D, et al.: Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs. Am J Hypertens 2004, 17:502–506. CrossRef
- Statins and proteinuria
Current Atherosclerosis Reports
Volume 7, Issue 5 , pp 351-357
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. Department of Nephrology & Hypertension, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A51, 44195, Cleveland, OH, USA